Boehringer Ingelheim Inks €410M Deal With Kyowa Kirin
Pharmaceutical giant Boehringer Ingelheim announced Friday that it had entered into a €410 million ($449 million) licensing agreement with Japanese pharmaceutical company Kyowa Kirin to develop a new treatment for fibro-inflammatory...To view the full article, register now.
Already a subscriber? Click here to view full article